Rupak Shivakoti, PhD, MSPH

CRS:

BJMC

Role:

Investigators

Position:

Investigator

Rupak Shivakoti, PhD, MSPH, is an Assistant Professor of Epidemiology at Columbia University Mailman School of Public Health, and a member of the faculty at the Johns Hopkins Center for Clinical Global Health Education. His formal training is in immunology, infectious diseases, and epidemiology.
 
Dr. Shivakoti’s primary research interest focuses on the central role of inflammation in HIV and TB outcomes, both in adult and maternal-infant populations. In addition, he is interested in the relationship of nutrition and gut microbiome with inflammation and health outcomes. He is the PI of NIH-funded projects related to these topics and conducted in diverse international settings, with a strong focus in India. More about Dr. Shivakoti's work can be found in the tabs below.
 
After completing his undergraduate degree in biology from DePauw University, Dr. Shivakoti received a MSPH in international health and a PhD in molecular microbiology and immunology from the Johns Hopkins Bloomberg School of Public Health. His PhD thesis, under the direction of Dr. Diane Griffin, focused on the innate and adaptive immune responses to the measles virus and measles vaccine. He completed his post-doctoral fellowship at JHU CCGHE with Dr. Amita Gupta serving as his mentor.

  • Investigator, NWCS 319, parent study A5175
  • Study Chair, NWCS 448, parent study A5331
  • Member, End-Organ Disease and Inflammation Transformative Science Group (Dec 2017-Nov 2019)

Categories

Leadership Committees
CRS
Roles

Clinical Trials

P2005: A Phase I/II Open-Label, Single-Arm Study to Evaluate...

This study is currently on hold. The study is designed to characterize the pharmacokinetics of DLM using a model-based...

Read More

A5361s: Pitavastatin to REduce Physical Function Impairment...

A5361s is a prospective study to determine the effects of pitavastatin on physical function. The study will enroll participants...

Read More

HPTN 069: A Phase II Randomized, Double-Blind, Study of the...

HPTN 069 is a phase II, four-arm, multisite, randomized, double-blinded trial. To assess the safety and tolerability of four...

Read More

A5314: Effect of LDMTX on Inflammation in HIV-infected...

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...

Read More

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More